Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 22 entities : Novartis ag save search
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.56%
H: 0.43%
C: -0.15%
cosentyx novartis treatment fda fda approval approval children
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
leqvio fda fda approval approval
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
leqvio novartis fda cholesterol
Sandoz launches authorized generic of Narcan® (naloxone hydrochloride) Nasal Spray 4 mg in US to help reverse opioid overdose, expanding access during surge in overdose deaths
Published: 2021-12-22 (Crawled : 22:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
narcan nasal spray opioid authorized
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
Published: 2021-12-22 (Crawled : 12:30) - globenewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
novartis gene therapy therapeutics therapy
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
Published: 2021-12-22 (Crawled : 07:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
ema application authorization biosimilar
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.